Cytogenetic Toxicity of Cisplatin in Bone Marrow Cells of Swiss Mice

REFERENCES

• de Serres FJ, Matsushima T. Meeting report: Mutagenesis and carcinogenesis by nitropyrenes and cancer chemotherapeutics. Mutation Res 1986; 64: 3–8.
   Web of Science ®Google Scholar
• William CJ, Whitehouse JMA. Cis-platinum: A new anti-cancer agent. Br Med J 1979; 1: 1689–1691.
   PubMedGoogle Scholar
• Rosenberg B. Fundamental studies with cisplatin. Cancer 1985; 55: 2303–2316.
   PubMed Web of Science ®Google Scholar
• Oliver RT. Testicular cancer. Curr Opin Oncol 1994; 6: 285-291.
   Google Scholar
• Greene MH. Is cisplatin a human carcinogen? J Nail Cancer Inst 1992; 84: 306–312.
   PubMedGoogle Scholar
• Kelland LR, McKeage MJ. Platinum drugs currently in clinical trial. Curr Opin Invest Drugs 1993; 2: 571–580.
   Google Scholar
• Weiss RB, Christian MC. New cisplatin drugs in develop-ment. Drugs 1993; 46: 362–377.
   Web of Science ®Google Scholar
• Tomson AJ. The interaction of platinum compounds with biological molecules. Rec Res Cancer Res 1974; 48: 38.
   Google Scholar
• Tinto A, Lippard SJ. Binding of the antitumor drug cis-diamminedichloroplatinum-II (cisplatin) to DNA. Biochem Biophys Acta 1985; 780: 167–180.
   PubMed Web of Science ®Google Scholar
• Harder HC, Rosenberg B. Inhibitory effects of antitu-mor platinum compounds on DNA, RNA and protein synthe-sis in mammalian cells in vitro. Int J Cancer 1970; 6: 207–216.
   PubMed Web of Science ®Google Scholar
• Zwelling LA, Kohn KW, Ross WE, Ewig RAG, Anderson T. Kinetics of formation and disappearance of a DNA cross-linking effect in mouse leukemia L1210 cells treat-ed with cis- and trans-diamminedichloroplatinum-II. Cancer Res 1978; 38: 1762-1768.
   Google Scholar
• Poirier MC, Reed E, Zwelling LA, Ozols RF, Litterst CL, Yuspa SA. Polyclonal antibodies to quantitate cis-diamminedichloroplatinum-H-DNA adducts in cancer patients and animal models. Environ Health Prospect 1995; 62: 89–94.
   Google Scholar
• Eastman A. Reevaluation of interaction of cis-dichloro (ethylenediammine) platinum-II with DNA. Biochemistry 1986; 25: 3912–3915.
   PubMed Web of Science ®Google Scholar
• Knox RJ, Friedlos F, Lydall DA, Roberts JJ. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum-II and cis-diammine (1,1-cyclobu-tane dicarboxylato)-platinum-II differs only in the kinetics of their interaction with DNA. Cancer Res 1986; 46: 1972-1979.
   Google Scholar
• Fichtinger-Schepman AMJ, Lohman PHM, Berends F. Interaction of antitumor drug cisplatin with DNA in vitro and in vivo. In: Schmahl D Kaldor JM, eds. Carcinogenicity of Alkylating Cytostatic Drugs, Lyon: IARC Scientific Publication, IARC, 1986; 78: 83–99.
   PubMedGoogle Scholar
• Sherman SE, Lippard SJ. Structural aspects of platinum anticancer drugs with DNA. Chem Rev 1987; 87: 1153–1181.
   Web of Science ®Google Scholar
• Burnouf D, Gauthier C, Chottard JC, Fuchs RPP. Single d (ApG) cis-diamminedichloroplatinum-II adduct-induced mutagenesis in Escherichia coli. Proc Nail Acad Sci USA 1990; 87: 6087–6091.
   PubMed Web of Science ®Google Scholar
• Perera FP, Motzer RJ, Tang D, et al. Multiple biological markers in germ cell tumor patients treated with platinum based chemotherapy. Cancer Res 1992; 52: 3558–3565.
   PubMed Web of Science ®Google Scholar
• Bubley GJ, Teicher BA, Ogata GK, Sandoval LS, Kusumoto T. Differences in in vivo and in vitro sequence spe-cific sites of cisplatin-DNA adducts formation and detection of dose-response relationship. Biochem Pharmacol 1994; 48: 145–153.
   PubMed Web of Science ®Google Scholar
• Bouyadi K, Salles B. Influence of DNA supercoiling on cisplatin toxicity in Escherichia coli K-12. Mutation Res 1995; 348: 25–31.
   PubMed Web of Science ®Google Scholar
• Giurgiovich AJ, Wan BAD, Anderson LM, Poirier MC. Tumorigenic levels of cisplatin induce rat fetal DNA adducts by prenatal exposure. Environ Mol Mutagen 1995; 25: 18.
   Google Scholar
• Brandsma JA, de Ruijter M, Visse R, et al. The in vitro more efficiently repaired cisplatin adduct cis-pt.GG is in vivo a more mutagenic lesion than the relative slowly repaired cis-pt. GCG adduct. Mutation Res 1996; 362: 29-40.
   Google Scholar
• Rice JA, Crothers DM, Pinto AL, Lippard SJ. The major adduct of the antitumor drug cis-diamminedichloroplat-Murn-ll with DNA bends the duplex by 40° toward the major groove. Proc Nail Acad Sci USA 1988; 85: 4158.
   PubMed Web of Science ®Google Scholar
• Plooy ACM, Van Dijk M, Lohman PHM. Induction and repair of DNA cross-link in Chinese hamster ovary cells treat-ed with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity and antitumor activity. Cancer Res 1984; 44: 2043–2051.
   PubMed Web of Science ®Google Scholar
• Lawley PD, Phillips DH. DNA adducts from chemother-apeutic agents. Mutation Res 1996; 355: 13–40.
   PubMed Web of Science ®Google Scholar
• Au11 JL, Allen RL, Bapat AR, Daron HH, Friedman ME, Wilson JF. The effects of platinum complexes on seven enzymes. Biochim Biophys Acta 1979; 57: 352–358.
   Google Scholar
• IARC. IARC Monographs on the evaluation of the car-cinogenic risk of chemicals to humans: some antineoplastic and immunosuppressive agents, Cisplatin. Lyon: IARC Scientific Publication, IARC, 1981; 26: 151–164.
   Google Scholar
• IARC. IARC Monographs on the evaluation of carcino-genic risks to humans: genetic and related effects: An updat-ing of selected IARC Monographs, from vols. 1-42, Cisplatin. Lyon: IARC Scientific Publication, IARC, 1987; Suppl. 6: 178-181.
   Google Scholar
• Sanderson BJS, Ferguson LR, Denny WA. Mutagenic and carcinogenic properties of platinum-based anticancer drugs. Mutation Res 1996; 355: 59–70.
   PubMed Web of Science ®Google Scholar
• Jackson MA, Stack HF, Waters MD. Genetic activity profiles of anticancer drugs. Mutation Res 1996; 355: 171–208.
   PubMed Web of Science ®Google Scholar
• Witt KL, Bishop JB. Mutagenicity of anticancer drugs in mammalian germ cells. Mutation Res 1996; 355: 209–234.
   PubMed Web of Science ®Google Scholar
• Rosenberg B, Van Camp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature (Lond.) 1965; 205: 698–699.
   PubMed Web of Science ®Google Scholar
• Yarema KJ, Wilson JM, Lippard SJ, Essigman JM. Effects of DNA adduct structure and distribution on the muta-genicity and genotoxicity of two platinum cancer drugs. J Mol Biol 1994; 236: 1034–1048.
   PubMed Web of Science ®Google Scholar
• Overbeck TL, Knight JM, Beck DJ. A comparison of the genotoxic effects of carboplatin and cisplatin in Escherichia coli. Mutation Res 1996; 362: 249–259.
   PubMed Web of Science ®Google Scholar
• Benedict WF, Baker MS, Haroun L, Choi E, Ames BN. Mutagenicity of cancer chemotherapeutic agents in the Sa/monella/microsome test. Cancer Res 1997; 37: 2209–2213.
   Google Scholar
• Anderson KS. Platinum-II complexes generate frameshift mutations in test strains of Salmonella typhimuri-urn. Mutation Res 1979; 67: 209–214.
   PubMed Web of Science ®Google Scholar
• Beck DJ, Fisch JE. Mutagenicity of platinum cooridina-tion complexes in Salmonella typhimurium. Mutation Res 1980; 77: 45–54.
   PubMed Web of Science ®Google Scholar
• Hannan MM. A comparative study of the cytotoxic and genotoxic effects of cisplatin and its analogue, TNO-6, in yeast. Mutation Res 1988; 198: 69–72.
   PubMed Web of Science ®Google Scholar
• Shevchenko VV, Grinikh LI, Ivanov VB. Study of the mutagenic effect of cis- and trans-dichlorodiammineplatinum-II on Crepis capillaris and Arabidopsis thalina. Soy Genet 1977; 13: 1037–1042.
   Google Scholar
• Shevchenko VV, Grinikh LI, Cheltsov PA, Ivanov VB, Shchelokov RN. Relationship between cytogenetic effect of platinum (II) complexes and their structure. Mutation Res 1983; 122: 329–335.
   PubMed Web of Science ®Google Scholar
• Woodruff RC, Valencia R, Lyman RF, Earle BA, Boyce JT. The mutagenic effect of platinum compounds in Drosophila melanogaster. Environ Mutagen 1980; 2: 133–138.
   PubMedGoogle Scholar
• Brodberg RK, Lyman RF, Woodruff RC. The induction of chromosome aberrations by cis-platinum (II) diamminedichloride in Drosophila melanogaster. Environ Mutagen 1983; 5: 285–297.
   PubMedGoogle Scholar
• Katz AJ. Genotoxic effects of cisplatin in somatic tissue of Drosophila melanogaster. Environ Mol Mutagen 1987; 10: 197–203.
   PubMed Web of Science ®Google Scholar
• Cizeau J, Decoville M, Leng M, Locker D. Deletions induced in the white and vermilion genes of Drosophila melanogaster by the antitumor drug cis-dichlorodiammineplat-Mum-II. Mutation Res 1994; 311: 8–31.
   Google Scholar
• Van Den Berg HW, Roberts JJ. Post replication repair of DNA in Chinese hamster cells treated with cisplatinum (II) diamminedichloride. Enhancement of toxicity and chromo-some damage by caffeine. Mutation Res 1975; 33: 279–284.
   Google Scholar
• O'Neill JP, Couch DB, Machanoff R, Sebastian S, Brimer PA, Hsie AW. A quantitative assay of mutation induc-tion at hypoxanthine-guanine phosphoribosyl transferase locus in Chinese hamster ovary cells (CHO/HGPRT system): utiliza-tion with a variety of mutagenic agents. Mutation Res 1977; 45: 103–109.
   PubMed Web of Science ®Google Scholar
• Zwelling LA, Bradley MO, Sharkey NA, Anderson T, Kohn KW. Mutagenicity, cytotoxicity and DNA crosslinking in V79 Chinese hamster cells treated with cis- and trans-pt (II) diamminedichloride. Mutation Res 1979; 67: 271–280.
   PubMed Web of Science ®Google Scholar
• Turnbull D, Popescu NC, Dipaolo JA, Myhr BC. Cis-platinum (II) diamminedichloride causes mutation, transforma-tion and sister-chromatid exchange in cultured mammalian cells. Mutation Res 1979; 66: 267–275.
   PubMed Web of Science ®Google Scholar
• Taylor RT, Carver JH, Hanna ML, Wanders DL. Platinum-induced mutations to 8-azaguanine resistance in Chinese hamster ovary cells. Mutation Res 1979; 67: 65–80.
   PubMed Web of Science ®Google Scholar
• Johnson NP, Hoeschele JD, Rahn RO, O'Neill JP, Hsie AW. Mutagenicity, cytotoxicity and DNA binding of platinum (II) chloroamines in Chinese hamster ovary cells. Cancer Res 1980; 40: 1463–1468.
   PubMed Web of Science ®Google Scholar
• Bradley MO, Patterson S, Zwelling LA. Thiourea pre-vents cytotoxicity and mutagenicity but not sister-chromatid exchanges in V79 cells treated with cis-diamminedichloroplat-Mum (1). Mutation Res 1992; 96: 67–74.
   Google Scholar
• Singh B, Gupta RS. Mutagenic responses of thirteen anticancer drugs on mutation induction at multiple genetic loci and on sister-chromatid exchanges in Chinese hamster ovary cells. Cancer Res 1983; 43: 577–584.
   PubMed Web of Science ®Google Scholar
• Bonatti S, Lohman PHM, Berends F. Induction of micronuclei in Chinese hamster ovary cells treated with Pt co-ordination compounds. Mutation Res 1983; 116: 149–154.
   PubMed Web of Science ®Google Scholar
• Nishi Y, Hasegawa MM, Taketoni M, Ohkawa Y, Inui N. Comparison of 6-thioguanine-resistant mutation and sister-chromatid exchanges in Chinese hamster V79 cells with forty chemical and physical agents. Cancer Res 1984; 44: 3270-3279.
   Google Scholar
• Fassina G, Collecchi P, Carlone S, Fulco RA, Esposito M. Mutagenic and cytotoxic effects in V79 Chinese hamster cells treated with cisplatin and cisplatin plus procaine. Mutation Res 1985; 144: 203–208.
   PubMed Web of Science ®Google Scholar
• Vogel R, Laschinski G, Spielman H, et al. In vitro stud-ies on genotoxicity and cytotoxicity of the anticancer drugs cis-platin and cofplaton, a caffeine-8-ether plus cisplatinum com-pound. Mutation Res 1991; 264: 225–230.
   PubMed Web of Science ®Google Scholar
• Jennerwein MM, Eastman A, Khokhar AR. The role of DNA repair in resistance of L1210 cells to isomeric 1,2-diamminecyclohexaneplatinum complexes and ultra violet irra-diation. Mutation Res 1991; 254: 89–96.
   PubMed Web of Science ®Google Scholar
• Rodilla V. Origin and evolution of binucleated cells and binucleated cells with micronuclei in cisplatin-treated CHO cul-tures. Mutation Res 1993; 300: 281–291.
   PubMed Web of Science ®Google Scholar
• Krishnaswamy G, Dewey WC. Cisplatin-induced cell killing and chromosomal aberrations in CHO cells: treated dur-ing G1 and S phase. Mutation Res 1993; 293: 161–172.
   PubMed Web of Science ®Google Scholar
• Pillaire MJ, Margot A, Villani G, Sarasin A, Defais M, Gentil A. Mutagenesis in monkey cells of a vector containing a single d (GpG) cis-diamminedichloroplatinum (II) adduct placed on codon 13 of the human H-ras proto-oncogene. Nucleic Acid Res 1994; 22: 2519-2524.
   Google Scholar
• Meyne J, Lockhart LH. Cytogenetic effects of cisplat-Mum (II) diamminedichloride on human lymphocyte cultures. Mutation Res 1978; 58: 87–97.
   PubMed Web of Science ®Google Scholar
• Meyne J, Lockhart LH, Arrighi FE. Nonrandom distrib-ution of chromosomal aberrations induced by three chemicals. Mutation Res 1979; 63: 201–209.
   PubMed Web of Science ®Google Scholar
• Wiencke JK, Cervenka J, Paulus H. Mutagenic activity of anticancer agent cis-dichlorodiammineplatinum (II). Mutation Res 1979; 68: 69–77.
   PubMed Web of Science ®Google Scholar
• Cipp DH, Singh RP. The mutagenic effect of cis-plat-Mum (II) diamminedichloride (CPDD) and CPDD plus caffeine. Mutation Res 1983; 122: 111–113.
   PubMed Web of Science ®Google Scholar
• Ohe T, Tsuda S, Sakata Y, Taniwaki M, Misawa S, Abe T. Cis-diamminedichloroplatinum (11)-induced sister-chromatid exchanges and chromosome aberration formation in cultured human lymphocytes and their inhibition by sodium thiosulfate. Mutation Res 1990; 244: 279–285.
   PubMed Web of Science ®Google Scholar
• Sanderson BJS, Johnson KJ, Henner WD. Dose dependent cytotoxic and mutagenic effects of antineoplastic alkylating agents on human lymphoblastoid cells. Environ Mol Mutagen 1991; 17: 238–243.
   PubMed Web of Science ®Google Scholar
• Jirsova K, Mandys V. Induction of micronuclei and granular chromatin condensation in human skin fibroblasts influenced by cisplatin (Cis-DDP) in vitro. Mutation Res 1994; 310: 37–44.
   PubMed Web of Science ®Google Scholar
• Morrison WD, Huff V, Colyer SP, Dufrain RJ, Littlefield LG. Cytogenetic effects of cisplatinum (II) diamminedichloride in vivo. Environ Mol Mutagen 1981; 3: 265–274.
   Web of Science ®Google Scholar
• Levine BS, Preache MM, Pergament E. Mutagenic potential of cis-dichlorodiammine platinum (II) in rodents. Toxicology 1980; 17: 57–65.
   PubMed Web of Science ®Google Scholar
• Tandon P, Sodhi A. Cis-dichlorodiammine platinum (II) induced aberrations in mouse bone-marrow chromosomes. Mutation Res 1985; 156: 187–193.
   PubMed Web of Science ®Google Scholar
• Kliesch U, Adler I-D. Micronucleus test in bone marrow of mice treated with 1-nitropropane, 2-nitropropane and cis-platin. Mutation Res 1987; 192: 181–184.
   PubMed Web of Science ®Google Scholar
• El-Tarras A, Adler I-D, Kliesch U, Ehling UH. Clastogenic effects of cisplatin in somatic and germinal cells of mice. Mutation Res 1988; 203: 220–221.
   Web of Science ®Google Scholar
• Adler I-D, El-Tarras A. Clastogenic effects of cis-diamminedichloroplatinum. I. Induction of chromosomal aberrations in somatic and germinal cells of mice. Mutation Res 1989; 211: 131–137.
   Google Scholar
• Wiencke JK, Cervenka J, Kennedy BJ, Prlina J, Gorlin R. Sister chromatid exchange induction by cis-platinum/adri-amycin cancer chemotherapy. Mutation Res 1982; 104: 131–136.
   PubMed Web of Science ®Google Scholar
• Nicklas JA, Lippert MJ, Hunter TC, O'Neill JP, Albertini RJ. Analysis of human HPRT deletion mutations with X-linked probes and pulsed field gel electrophoresis. Environ Mol Mutagen 1991; 18: 270–273.
   PubMed Web of Science ®Google Scholar
• Choudhury RC, Hasan A, Mahanty V. Effects of mer-curic chloride on mitotic, meiotic chromosomes and sperm in mice. Biol Zent bl 1995; 114: 369–377.
   Google Scholar
• Schmid W. The micronucleus test: An in vivo bone marrow method. In: Hus TC, eds. Cytogenetic assays of Environmental Mutagens, New Delhi: Oxford and IBH Publishing Co. 1982: 221-235.
   Google Scholar
• Kastenbaum MA, Bowman KO. Tables for determining the statistical significance of mutation frequencies. Mutation Res 1970; 9: 527–549.
   PubMed Web of Science ®Google Scholar
• IARC. IARC Monograph on the evaluation of the car-cinogenic risk of chemicals to humans. Some antineoplastic and immunosuppressive agents: Cyclophosphamide. Lyon: IARC Scientific Publication, IARC, 1981; 26: 165–202.
   Google Scholar
• IARC. IARC Monographs on the evaluation of carcino-genic risks to humans: genetic and related effects: an updating of selected IARC Monographs from vols. 1-42, Cyclophosphamide. Lyon: IARC Scientific Publication, IARC, 1987; Suppl. 6: 196-205.
   Google Scholar
• Mavournin KH, Blakey DH, Cimino MC, Salamone MF, Heddle JA. The in vivo micronucleus assay in mam-malian bone marrow and peripheral blood. A report of the U.S. Environmental Protection Agency Gene-Tox Program. Mutation Res 1990; 239: 29–80.
   PubMed Web of Science ®Google Scholar
• Krishna G, Petrere J, Anderson J, Theiss J. Use of cyclophosphamide as a positive control in dominant lethal and micronucleus assays. Mutation Res 1995; 335: 331–337.
   PubMed Web of Science ®Google Scholar
• Sladek NE. Metabolism of cyclophosphamide by rat hepatic microsomes. Cancer Res 1971; 31: 901–908.
   PubMed Web of Science ®Google Scholar
• Beck DJ, Burbaker RR. Mutagenic properties of cis-platinum (II) diammine-dichloride in Escherichia coli. Mutation Res 1975; 27: 181–189.
   PubMed Web of Science ®Google Scholar
• Bouyadi K, Villani G, Salles B. Resistance to cisplatin in an E. coli B/r NalR mutant. Mutation Res 1993; 294: 77–87.
   PubMed Web of Science ®Google Scholar
• Burnouf D, Daune M, Fuchs RPP. Spectrum of cisplatin induced mutations in Escherichia coli. Proc Nat Acad Sci USA 1987; 84: 3758–3762.
   PubMed Web of Science ®Google Scholar